

Includes stem cells
in drug discovery and
toxicology briefing day

Register before 29 February
and save up
to £293!

& European Stem Cells Regenerative Medicine Congress 2008

13 – 15 May 2008, Royal Horseguards Hotel, London, UK



Transform.

The future of stem cells

Help shape the direction of stem cells
and regenerative medicine

Commercialise your business

Bridge the gap between biotech and
pharmaceutical companies

Exclusive investment opportunities

Engage with the wider stem cell
investment community

Forge meaningful partnerships

Build successful alliances to drive your
business forward

Global gathering

Meet the key opinion leaders from
around the World

Keynote representation



Dr Alan Trounson
President
California Institute
of Regenerative
Medicine



Bernard Siegel
Executive Director
Genetics Policy
Institute



Dr Alan Russell
Director
McGowan Institute
for Regenerative
Medicine

Additional key speakers include



Dr Thomas Okarma
Chief Executive Officer
Geron



Dr Alan Lewis
Chief Executive Officer
Novocell



Dr Gail Naughton
Chief Executive Officer
Histogen



Dr Michael West
Chief Executive Officer
Biotime



Dr Michael Hunt
Chief Executive Officer
ReNeuron



Dr Alfred Sapse
President
Stem Cell Pharma, Inc.



Dr John McNeish
Senior Director
Pfizer Global R&D



Dr Ajan Reginald
Global Head of Emerging
Group Research
Roche



Hugh Ilyine
Chief Operating Officer
Stem Cell Sciences

The business behind stem cells

- Moving the industry from bench to bedside: emerging into a competitive market place
- Case study updates: commercial expectations, clinical trial progress and best practice
- Understand regulatory, IP and reimbursement guidelines
- Drug discovery day: undertake groundbreaking stem cell research for immediate application
- Enhanced networking: meet your peers, share knowledge and do business!

Our sponsors and exhibitors



Lonza



Our partners

Organised by



Transform.

The complete stem cell event for science,

The global market for stem cell products and services is already valued at approximately €20bn and is forecast to grow almost threefold by 2010 to €54bn. This last year has seen a proliferation of interest in this lucrative field, seeing new consortia emerge and new strategies for funding and development. Stem cell research continues to make significant advances towards valuable treatments for serious diseases such as Parkinson's, Diabetes, Stroke and Cancer.

Despite these advances, the development of stem cell-derived products remains a virtually untapped profit centre for the biotechnology and pharmaceutical industries.

Challenges of regulation, IP and investment stand in the way of large scale business development and existing structures are subject to change and expiration in the coming months.

The 3rd annual *European Stem Cells and Regenerative Medicine Congress* focuses on bridging the gaps between researchers,

investors and manufacturers. Industry leaders will discuss working practice and commercial models for a successful business, charting the regulatory landscape and understanding the funding options as they emerge.

Who will attend?

- Pharmaceutical manufacturers
- Biotechs
- Contract research organisations
- Contract manufacturing organisations
- Equipment and technology providers
- Government research institutes
- Academia and clinicians
- Regional development agencies
- Venture capitalists & law firms
- Research foundations
- Stem cell research centres

The congress will provide the opportunity for updates in leading clinical research, new patenting legislation, exciting business models and the consideration of a global stem cell body working together for therapeutic and commercial advances.



Advisory Board

The congress has been developed with advice from leading experts in the field of stem cells and regenerative medicine. Our advisory board comprises individuals at the forefront of stem cell research and development.



Dr Chris Mason
Director, Regenerative Medicine
Bioprocessing Unit
University College London

At the forefront of this field, Chris is an alumnus of Imperial College and St. Thomas' Hospital and is a Fellow of the Royal College of Surgeons as well as holding a PhD in Biochemical Engineering (UCL.) Chris has expertise in industrial consultancy and technology companies and is co-organiser of the London Regenerative Medicine Network.



Hugh Ilyine
Chief Operating Officer
Stem Cell Sciences

When Hugh joined the company in 2000 he brought extensive experience in developing, registering, manufacturing and distributing products in the agrochemical and bioscience sector. Hugh has managerial and directorial experience on both a national and international level and in his current role he oversees the Worldwide business operations of Stem Cell Sciences.



Dr Tim Allsopp
Chief Scientific Officer
Stem Cell Sciences

After 12 years as a leading academic with a developing interest in stem cell biology Tim joined Stem Cell Sciences Ltd to utilize pluripotent, embryonic stem cells in the discovery of unique human disease treatments and cures. Current responsibilities include directing the research in ES biology, development of ES-based technologies for applications in gene & drug discovery and business development.



Dr Stephen Minger
Director, Stem Cell Biology
Laboratory, Wolfson Centre for
Age-Related Diseases
King's College London

Stephen was granted one of the first licenses for the derivation of human ES cells and his group generated the first human ES cell line in the UK. Stephen collaborates with UK clinical groups and is a co-organiser of the London Regenerative Medicine Network.

“ No other conference attracts such a mix of leading scientists working in the private industry in all aspects relating to stem cell biology. This conference provided a forum to see how small and big steps are being taken in that direction ”

Dr Ignacio Munoz-Sanjuan,
Senior Scientist, **Amgen**

5 easy ways to register

Phone: +44 (0) 207 242 2324

Fax: +44 (0) 207 242 2320

Online: www.lifescienceworld.com/2008/stemcells

Email: caroline.thoresen@terrapinn.com

Post: Terrapinn Ltd, Wren House,
43 Hatton Garden, London,
EC1N 8EL, UK

business strategy and networking



A Terrapinn event is an experience



Our online "contact" system allows you to make initial contact, arrange meetings and begin your networking with your fellow delegates prior to the event. It allows you to take full advantage of the extended breaks and dedicated networking time by planning in advance the meetings that will drive your business forward.

This is a revolutionary, exciting, quick and non-pressurised way to meet fellow delegates and industry peers in one fifty minute session. These brief meetings are the starting point for conversation and networking throughout the congress. Be sure to bring along plenty of business cards for this session, which is where long lasting and fruitful relationships begin.



The congress programme includes several panel sessions. These are chat show style sessions creating an interactive environment rather than a lecture. The panellists are chosen for their views and lively debate is encouraged. This is your chance to interact and put your questions to the panel to ensure that the experts can answer the questions that are relevant to your business.

Terrapinn's networking drinks receptions allow you to continue the conversations you begin during the congress. Join us to relax with your peers and experience toasting the developments in your industry.



“ Well done with the conference!
I enjoyed it and found it
very useful ”

Dr Aaron Chuang,
Neurodegeneration Department,
Neurology and Gastrointestinal
Centre of Excellence for
Drug Discovery,
GlaxoSmithKline



Overlooking the River Thames, The Royal Horseguards Hotel is perfectly positioned in the historic heart of London. Its unique location and grade I listed building makes it one of the capital's most sought after hotels and it encapsulates the very best of British hospitality. Take advantage of the highest levels of service and grand Victorian style whilst you relax and do business in this luxurious venue.

What's in it for you? Benefits of attending

- Latest research in the field of stem cell therapeutics through exposition of multiphase clinical trials
- Funding opportunities for emerging therapies
- New and established stem cell companies offer their insights
- The most recent consortia approach to stem cell business development
- Business models for commercialising your therapy
- Developments within the IP regulatory and reimbursement landscape
- Contract and clinical manufacturing advancements
- The development of an international industry association for regenerative medicine

50% discount
for academia/
government/non-for profit
representatives.

Your key event to
balance science with
strategy.

Book before 29 February and save up to £293!

Book now, fax back the registration form
to +44 (0) 207 242 2320

European Stem Cells and Regenerative Medicine Congress

Transform.

Day one Wednesday 14 May 2008

08.00 Registration and coffee

09.00 Chairman's opening remarks

Dr Chris Mason, Director, Regenerative Medicine Bioprocessing Unit, **University College London**

STEM CELL DEVELOPMENT: EMERGING INTO A COMPETITIVE MARKETPLACE

09.10 Keynote presentation: comparative merits of cell production methods for regenerative medicine

- New methods of deriving primate embryonic stem cells, in relation to the established derivation from embryos
- Political, business and regulatory considerations of stem cell development
- Translational stem cell science and the vision of CIRM

Dr Alan Trounson, President, **California Institute of Regenerative Medicine**

09.40 Keynote presentation: unlocking the cells: critical public-policy perspectives

- How public policy directly affects stem cell research
- Establishing a positive legal framework to advance regenerative medicine
- Working with many bodies to ensure maximum development in the industry

Bernard Siegel, Executive Director, **Genetics Policy Institute**

10.10 Keynote presentation: regenerative medicine: past, present and future

- Pioneering regenerative medicine and the outlook for the future
- The scientific impact of a methodological shift
- Possible timescales for change and potential for the advancement of regenerative medicine and tissue engineering

Dr Alan Russell, Director, **McGowan Institute for Regenerative Medicine**

10.40



This is a revolutionary, exciting, quick and non-pressured way to meet fellow congress delegates and industry peers in one fifty minute session. These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and fruitful relationships begin. Please make sure you bring lots of business cards!

- Meet...move on... meet...move on...meet!
- Exchange business cards with fellow congress delegates, speakers and moderators
- The best networking session you've ever experienced

11.30 Morning coffee

FUNDING AND OPERATION: SECURING INVESTMENT FOR STEM CELL BUSINESSES

12.00 Closing the gap between biotech and big pharmaceutical companies

- Are big pharmaceutical companies ready to invest in stem cell businesses?
- Exploring the logistics of funding for small research bodies alongside big pharmaceutical companies
- Talent retention issues and the import of liberalised funding

Hugh Ilyine, Chief Operating Officer, **Stem Cell Sciences**

12.30 Funding and operating a quoted UK stem cell business

- Reconciling business needs and investor expectations
- Funding sources and funding strategies
- The challenges of funding under the present regulatory system

Dr Michael Hunt, Chief Executive Officer, **ReNeuron**

13.00 Lunch

14.00 Venture capital and regenerative medicine

- Recent developments in venture investment
- Comparison of EU and US funding allowance
- Biotech companies as investment potential

Gregory Bonfiglio, Managing Director, Partner, **Proteus Venture Partners**

14.30 Panel session: Investment and partnering opportunities for biotech: mid-stage and post clinical enterprises

- Securing multifaceted funding options for biotech business
- Maximising valuation to a prime investment area
- Emergence of high net worth investment: The shape of things to come?

Moderator: Gregory Bonfiglio, Managing Director, Partner, **Proteus Venture Partners**

Panellists: Dr Ajan Reginald, Global Head of Emerging Group Research, **Roche**

Roger Guidi, Vice President, Venture Capital,

Johnson and Johnson Development Corporation

Sir Richard Sykes, Chairman, **UK Stem Cell Foundation**

EXPANSION OF CLINICAL AUTOMATION PROCESSES

15.15 Mapping the human embryome: multiplex strategies for the purification and characterisation of human embryonic progenitor cells

- Newly patented technologies for in house product lines
- Transfer of manufacturing capabilities with investment capital and changes in legislation
- Ensuring standardisation and safety protocol on a large scale

Dr Michael West, Chief Executive Officer, **BioTime**

15.45 Cell culture automation and expression of pluripotency: automotive processes

- Multiple uses of single cells: establishing cost effective automation
- Scale-up and automation of HESC cultures and cryo-conservable somatic stem cells
- Reversible engineering: post and mid-clinical models

Professor Oliver Brüstle, Director, Institute of Reconstructive Neurobiology, **University of Bonn** and Scientific Director, **LIFE & BRAIN**

16.15 Afternoon tea

MULTI-PHASE CLINICAL TRIALS IN THERAPEUTIC STEM CELL APPLICATIONS

16.45 Case study: neo-bladder trials and establishing a regulatory precedent

- Clinical trial and product overview
- Entering uncharted regulatory terrain and setting a precedent
- The unique challenges that relate to developing a regenerative medical product

Dr Elyse Seltzer, Chief Medical Officer, **Tengion**

17.15 Case study: heart muscle regenerative therapy clinical trial results

- Exposition of trials and phasing
- Clinical data and outcomes
- Next phase and regulatory approaches to development

Dr Michael Siani-Rose, President and Founder, **Theragen**

17.45 Panel session: the clinical roadmap for developing a stem cell derived product

- Common challenges in clinical trials for regenerative products
- Regulatory and developmental concerns

Moderator: Dr Chris Mason, Director, Regenerative Medicine Bioprocessing Unit, **University College London**

Panellists: Dr Paul Kemp, Chief Executive Officer, **Intercytex**

Dr Randal Mills, Chief Executive Officer, **Osiris Therapeutics**

Dr Nicolas L'Heureux, Chief Scientific Officer, **Cytograft**

18.30 Close of day one followed by networking drinks reception

Day two Thursday 15 May 2008

08.00 Registration and coffee

09.00 Chairman's opening remarks

Dr Stephen Minger, Director, Stem Cell Biology Laboratory, Wolfson Centre for Age Related Diseases, **Kings College London**

MOTION TOWARDS THERAPEUTIC STEM CELL RESEARCH

09.10 Cells as pills: developing saleable stem cell products

- Donor to shelf: creating a viable and useful product in the stem cell field
- Autologous and non-autologous cells
- The regulatory framework and development strategies

Dr Thomas Okarma, Chief Executive Officer, **Geron**

09.40 Case Study: embryonic stem cell therapy for diabetes

- Contract manufacturing logistics
- Post-clinical roll-out
- Marketing an emerging product

Dr Alan Lewis, Chief Executive Officer, **Novocell**

10.10 Challenges of commercialising stem cell therapies and creating a successful business model

- Regulatory, manufacturing, and reimbursement hurdles faced by tissue engineered products
- Lessons learned from Advanced Tissue Sciences
- Redefining regenerative medicine products with a new business model for short and mid-term commercialisation of human cell derived products

Dr Gail Naughton, Chief Executive Officer, **Histogen**

10.40 Morning coffee

DEVELOPMENTS WITHIN THE REGULATORY, IP AND REIMBURSEMENT LANDSCAPE

Session Chairman:

Dr Ivor Elrifi, Co-Chair Intellectual Property Section, **Mintz Levin**

11.10 Reimbursement: funding logistics for IP protection and biotech autonomy

- Ensuring transparency in operations between biotech and big pharmaceutical companies
- The importance of initiating an early reimbursement dialogue
- Reimbursement strategies and safeguards

Dr Geoff Mackay, Chief Executive Officer, **Organogenesis**

11.40 How will advanced therapies regulation affect development and manufacture of stem cell based products?

- Negotiating the new regulative guidelines
- The UK model: working with changing guidelines and exclusive criteria
- Working practically with the advanced therapies regulation and realistic timescales for application

James Lawford Davies, Solicitor, **Clifford-Chance** and **University of Newcastle**

12.10 Navigating the stem cell IP landscape: future and existing patentability

- What is patentable? IP rights and problems within the challenging and saturated patent arena
- New patenting legislation for stem cell products and its implications for biotech and pharmaceutical co-operation
- Existing patents and the impact of their expiration

Gareth Williams, Solicitor, **Marks and Clerk**

12.40 FDA regulation and negotiating the regulatory issues for regenerative medicine

- Present regulation for emerging stem cell therapy products
- ATMP legislation and existing legislative procedures
- Initiating business using current FDA regulations

Dr Steven Bauer, Chief of the Laboratory of Stem Cell Biology, Division of Cellular and Gene Therapies, **Centre for Biologics Evaluation and Research, FDA**

13.10 Lunch

CONTRACT MANUFACTURING: SCALING-UP AND DEVELOPING A PROFITABLE BUSINESS MODEL FOR POST-CLINICAL OPERATION

14.10 Great phase II clinical results: preparing for commercial-scale production

- What should I be thinking about in process development and manufacturing of my cell therapeutic?
- What process developing changes are needed prior to process validation?
- Will my raw materials and suppliers meet regulatory scrutiny?
- How will cost of goods goals be met?
- Is my production facility ready for inspection?

David Smith, Head of Cell Therapy, **Lonza**

14.40 An integrated approach for accelerated development of cellular therapies

- Optimising manufacturing processes early in the product development cycle
- Leading edge technologies for cell separation, expansion and characterisation
- Inherent challenges of scale up and application of technical solutions

Dr Stewart Craig, Chief Technical Officer and Vice President, **Progenitor Cell Therapy**

15.10 Afternoon tea

15.40 Contract manufacturing for the regenerative medicine field

- Optimising manufacturing processes
- Manufacturing developments and creating a forward looking model for regenerative medicine scale-up
- Ensuring accurate and transparent operations for large scale productions

Richard Archer, Managing Director, **Two BC Ltd.**

THE NECESSITY FOR AN INTERNATIONAL INDUSTRY ASSOCIATION FOR REGENERATIVE MEDICINE

16.10 Panel session: does the stem cell industry need a regulatory body?

- The lack of historical precedent for stem cell biotech lobby groups
- Essential criteria for developing a regulative body
- How to ensure representative regulation in line with ATMP standards

Moderator: Dr Chris Mason, Director, Regenerative Medicine Bioprocessing Unit, **University College London**

Panellists: Dr Geoff Mackay, President and Chief Executive Officer, **Organogenesis**

Gregory Bonfiglio, Managing Director, Partner, **Proteus Venture Partners**

Dr Alan Russell, Director, **McGowan Institute for Regenerative Medicine**

16.55 Chairman's closing remarks and close of congress

Book before 29 February 2008 and save £293.17!

Leading industry experts have already confirmed their participation, register today to join them.

Fax back the registration form to +44 (0) 207 242 2320 or register online at www.lifescienceworld.com/2008/stemcells

Briefing day: stem cells in drug discovery and toxicity Monday 13 May 2008

08.00 Registration and coffee

09.00 Chairman's opening remarks: Dr Tim Allsopp, Chief Scientific Officer, **Stem Cell Sciences**

DEVELOPING CONSORTIA TO NEGOTIATE FUNDING, RESEARCH AND LEGISLATIVE CHALLENGES

09.10 Stem Cells 4 Safer Medicine (SC4SM): the first major public-private partnership in toxicology research

- Benefit driven co-operation for stem cell businesses
- Open protocols and standardised systems in stem cell technology which enable consistent differentiation of stem cells into stable homogenous populations of particular cell types
- Physiologically relevant phenotypes suitable for toxicology testing in high throughput platforms

Dr Philip Wright, Chairman, **SC4SM**, Director of Science and Technology, **ABPI**

09.40 UK policy for stem cell drug discovery and strategies for simplifying the funding and development process

- Legislation that allows PP funding and development initiatives
- Why now? The PPP as a case study for immediate public investment
- Governmental involvement and public interest development for stem cell partnerships

Mark Bale, Deputy Director of Scientific Development & Bioethics, **Department of Health, UK**

10.10 How can partnerships develop stem cell innovation?

- Developing consortia driven models for stem cell businesses based on their unique challenges
- Increasing the profile, impact and profitability of stem cell derived products
- Drug discovery and safety as a starting point for stem cell consortia: their potential in this field and in the wider therapeutic landscape

Dr Ajan Reginald, Global Head of Emerging Group Research, **Roche**

10.40 Morning coffee

STEM CELLS AS TOOLS IN DRUG DISCOVERY

11.10 Approaches to drug discovery using diabetic, cardiovascular, and hepatic biology

- Demonstrating the utility of embryonic stem cells as research tools for drug discovery
- Drug screening developments and progress
- Developing a clinically relevant biological system that offers an unprecedented level of transfer for effective drugs

Dr Ralph Snodgrass, Chief Executive Officer, **Vistagen Therapeutics Inc.**

11.40 An appraisal of human stem cell products for drug discovery

- Rationale for neural stem cells as drug targets
- Assessing the areas where industry and academia can effectively work together
- Recent findings and promise of this technology

Dr Aaron Chuang, Drug Discovery Stem Cell Coordinator and Manager of Cellular Neurobiology, Neurodegeneration Research Department, **GlaxoSmithKline**

12.10 Cortisol, telomerase and stem cells

- Identifying high cortisol as an inhibitor of stem cells
- Using telomerase as a diagnostic tool in stem cell research
- Compounds extending telomerase chain and activity

Dr Alfred Sapse, President, **Stem Cell Pharma Inc.**

STEM CELL USAGE IN TOXICOLOGY

12.40 Human embryonic stem cells as tools in drug discovery and toxicity testing

- Cellartis as a Swedish/British company, funding and external relations

- The biotech niche and potential for commercialisation
- The dependence of hESC-platform for industrialisation possibilities

Dr Mats Lundvall, Chief Executive Officer, **Cellartis**

HESC-derived specialised cells and their application in the drug discovery process

- Focus: derivation of hepatocytes and their industrial potential
- Derivation of cardiomyocytes and beta-cells
- Products and commercial possibilities with hESC-derived specialised cells

Dr Petter Björquist, Senior Principal Scientist, Head Hepatocyte/Beta-cell Development, **Cellartis**

13.10 Lunch

14.10 Toxicity testing: traditional approaches versus predictive toxicology

- Potential applications and benefits of predictive toxicology
- In vivo imaging for toxicology informatics
- Multidimensional modelling

Professor Ian Cotgreave, Director of Molecular Toxicology, Safety Assessment, **AstraZeneca**

NOVEL STRATEGIES FOR TARGET DISCOVERY

14.40 A novel high-throughput method for stem cell differentiation

- New research findings in throughput maximisation
- Harnessing small molecules for asymmetric division and target replication
- Accuracy benchmarks for efficient experimental procedures

Dr John McNeish, Senior Director, **Pfizer Global R&D**

15.10 High throughput techniques in drug discovery

- High throughput with ensured validity in muscle cells
- Cell washing and priming procedures for discovery and toxicology
- Demonstration of automated procedures for the formatting of human stem cells

Dr Tim Allsopp, Chief Scientific Officer, **Stem Cell Sciences**

15.40 Afternoon tea

16.10 High throughput differentiation and licensing human embryonic stem cells

- Generating information on the biochemical mechanisms of differentiation
- Developing drugs that affect pathways, using proprietary technologies
- Modelling these products and developing a saleable product

Dr Yen Choo, Chief Executive Officer, **Plasticell**

16.40 Metabolomics and pluripotency in developing novel targets for drug discovery

- Developmental toxicity in humans and recent findings
- Animal models and interpretation
- Consortia for drug safety and working with research institutions

Dr Gabriela Gebrin Cezar, Assistant Professor, **University of Wisconsin-Madison, Department of Animal Sciences**

17.10 Close of briefing day followed by drinks reception



The networking drinks receptions are a great opportunity to meet other attendees after the congress day ends. Held at the end of the pre-congress briefing day, this is your perfect opportunity to network with your peers in an informal setting. These are relaxed, informal and entertaining events.

Driving stem cell commercialisation forward at an unsurpassed forum...


5 simple questions to determine your involvement

- Q.1** Do you want to do business with senior decision makers from the leading pharmaceutical, biotechnology and research institutions from the stem cell arena?
- Q.2** Are you able to help companies further their translational therapies?
- Q.3** Can you provide a solution to funding, regulation and price reimbursement to advance the stem cell market?
- Q.4** Do you have the know how to conduct clinical research or contract manufacture within regenerative medicine?
- Q.5** Can you see the advantages of delivering your precise message to your target audience as well as meet prospective customers?

If your answer is yes to any of these questions then the *European Stem Cells & Regenerative Medicine Congress 2008* is the most important place for you to be.

- Contract research organisation
- Contract manufacturing organisation
- Equipment providers
- Biotechnology companies
- Pharmaceutical manufacturers
- Consultants
- Law firms
- Venture capitalists

Delegate by job title



Raise your companies' profile

Increase your chances of being chosen as the logical choice of supplier, when they hear and see how you can exceed their needs.

Don't pass business opportunities by whilst your competitors walk away with them.

“ Thanks for a great meeting, very informative and excellent diverse topics ”

Mary Meyer,
Director Cell and Tissue Technology
Business Development,
BD Technologies


Find your all year round marketing solution

There are a limited number of opportunities for you to get your message across to the stem cell industry, so act now to avoid disappointment.

Put simply, you can't afford to miss out!

This congress helps you overcome common business development hurdles, like access to the right people and face to face networking with the right people.

Organisation by industry type



Our sponsors and exhibitors



Our media partners



Join our existing partners at this prestigious event.

Contact Ince Saleem at
ince.saleem@terrapinn.com or
call +44 (0) 207 092 1323
to tailor your package

Response form

Fax back to +44 (0) 207 242 2320

☐ **Yes!** I am interested in sponsorship opportunities.
Please contact me immediately

☐ **Yes!** I am interested in exhibiting.
Please contact me immediately

Name: Job title:

Company: Address:

Postcode: Country:

Tel: Fax: Email:

Event code: 14/1366

European Stem Cells and Regenerative Medicine Congress

Registration form



13 – 15 May 2008, The Royal Horseguards Hotel, London, UK

5 easy ways to register

Phone: +44 (0) 207 242 2324
Fax: +44 (0) 207 242 2320
Online: www.lifescienceworld.com/2008/stemcells
Email: caroline.thoresen@terrappinn.com
Post: Terrappinn Ltd, Wren House,
43 Hatton Garden London, EC1N 8EL, UK

Yes, please register me for:

Package	Dates	Received before 29 February 2008	Received after 1 March and before 28 March 2008	Received after 29 March 2008
<input type="checkbox"/> Gold pass – all 3 days	13 – 15 May 2008	£2,245.50 + VAT £392.96 = £2,638.46 SAVE £293.17!	£2,370.25 + VAT £414.79 = £2,785.04 SAVE £146.59!	£2,495 + VAT £436.63 = £2,931.63
<input type="checkbox"/> 2 day congress	14 – 15 May 2008	£1,615.50 + VAT £282.71 = £1,898.21 SAVE £210.92!	£1,705.25 + VAT £298.42 = £2,003.67 SAVE £105.46!	£1,795 + VAT £314.13 = £2,109.13
<input type="checkbox"/> Pre-congress briefing	13 May 2008	£877.50 + VAT £153.56 = £1,031.06 SAVE £114.57!	£926.25 + VAT £162.09 = £1,088.34 SAVE £57.29!	£975 + VAT £170.63 = £1,145.63

☐ **50% discount for government, academia and non profit organisations subject to Terrappinn approval**

*Payment terms are 14 days. Registration fee includes lunch, refreshments and full conference documentation. The fee does not include hotel accommodation.

Register before 29 February and **save up to £293!**

Corporate groups. Yes, I want to send the team and save even more.

Delegates	Package	Normal price	Group price	Total savings
<input type="checkbox"/> 3	Gold pass	£7,485 + VAT £1,309.88 = £8,794.88	£6,736.50 + VAT £1,178.89 = £7,915.39	SAVE £879.49!
<input type="checkbox"/> 6	Gold pass	£14,970 + VAT £2,619.75 = £17,589.75	£11,976 + VAT £2,095.80 = £14,071.80	SAVE £3,517.95!
<input type="checkbox"/> 8	Gold pass	£19,960 + VAT £3,493 = £23,453	£14,970 + VAT £2,619.75 = £17,589.75	SAVE £5,863.25!

**Corporate booking prices cannot be used in conjunction with any other promotional prices

Attendee details

	Mr/Mrs/Ms	Full name	Job title	Telephone	Email
1					
2					
3					
4					
5					

If you are booking more delegates, please attach a separate sheet with details of all attendees. Alternatively call +44 (0) 207 242 2324

Company details

Signatory must be authorised to sign on behalf of contracting organisation

Name:.....

Job title:.....

Authorising signature:.....

Email:.....

Organisation name:.....

Industry:.....

Address:.....

Postcode:.....Country:.....

Tel:.....Fax:.....

Method of payment

Payment terms are 14 days. The conference registration pack will be sent to you once payment has been received.

☐ Bank Transfer ☐ Crossed cheque payable to Terrappinn Ltd
☐ Diners Club ☐ Visa ☐ American Express ☐ Mastercard

Card number:

Card holder's signature:

Expiry date: Security code:

Bank Transfers: Account name: Terrappinn Limited, Sort code: 30-94-31, Bank Account Number: 0602538, Bank Name & Address: Lloyds TSB, 6 Holborn Circus, London EC1N 2HP, Swift Address: LOYDGB2L, IBAN: GB06 LOYD 3094 3100 6025 38, BIC: LOYDGB21037. **Reference: please quote 14/1366 and the delegate's name**

For official use only

Received: ☐ Date: Code 14/1366/A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Venue and hotel accommodation

Venue: The Royal Horseguards, 2 Whitehall Court, Whitehall, London, SW1A 2EJ
Tel: 0870 333 9122 Fax: 0870 333 9222 www.theroyalhorseguards.co.uk

Hotel accommodation: The conference fee does not include accommodation. Terrappinn has obtained specially discounted rates for all attendees. A hotel booking form will be sent to all registered attendees. Please book your accommodation early to avoid disappointment.

Data Protection

Terrappinn (or its agents) may contact you by mail, phone or email about products and services offered by Terrappinn and its group companies, which Terrappinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Terrappinn may also disclose your contact details to such third parties to enable them to contact you directly. Certain entities to which Terrappinn discloses your contact details are located in territories overseas which have fewer legal safeguards to protect personal data. By returning this form to us, you agree to our processing of your personal information in this way. Please tick the appropriate box if you do not wish to receive such information from:

☐ the Terrappinn group; ☐ or reputable third parties.

Cancellation

1. Should you be unable to attend, a substitute delegate is welcome at no extra charge.
2. Should you wish to cancel completely a charge of 50% of the registration fee, plus £150 (+ VAT) administrative charge will be made for cancellations received in writing at least 30 days prior to the conference start date.
3. Alternatively, you may choose a credit note for the full value of the registration price (valid for 1 year), which may be put towards another Terrappinn event.
4. The company regrets that no cancellations will be accepted within 30 days of the conference start date. Prepayments will not be refunded and invoiced sums will be payable in full, except in cases where it has been possible to mitigate loss.
5. Course documentation will, however be made available to the delegate. Terrappinn reserves the right to alter the programme without notice.

Insert your voucher code

Code: